Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source.

OBJECTIVES To determine whether whole bladder photodynamic therapy after intravesical administration of 5-aminolevulinic acid using a white light source would destroy urothelial carcinoma. We sought to define the optimal target group of patients for this therapy. The side effects of treatment were also assessed. METHODS We performed whole bladder photodynamic therapy with 100 J/cm(2) white light 2 to 4.5 hours after intravesical administration of 17% 5-aminolevulinic acid in 12 patients with recurring, multifocal, Stage pTa, grade I to III, urothelial tumors of the bladder and carcinoma in situ. RESULTS Immediately after whole bladder irradiation, histologic examination of biopsies taken from flat suspicious lesions showed no viable cells; remnants of malignant cells were found in papillary tumors. Of the 12 patients, 11 returned for follow-up examination. At a median follow-up of 18 months (range 3 to 25), 3 of the 7 patients with carcinoma in situ and 2 of the 4 patients with papillary tumors were free of disease. In all patients, urinary frequency and urgency subsided within 3 weeks. No decreased bladder capacity or systemic side effects were observed. CONCLUSIONS Our preliminary data show that whole bladder photodynamic therapy with intravesically applied 5-aminolevulinic acid using a white light source is effective in destroying flat malignant lesions of the bladder such as carcinoma in situ. The procedure is easy to perform and is not associated with any major side effects. The findings warrant long-term and multicenter studies.

[1]  H Stepp,et al.  Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. , 2001, The Journal of urology.

[2]  Q. Peng,et al.  5‐Aminolevulinic Acid‐Based Photodynamic Therapy: Principles and Experimental Research , 1997, Photochemistry and photobiology.

[3]  R Baumgartner,et al.  Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. , 1996, British journal of urology.

[4]  D. Kessel,et al.  Hemodynamic effects of 5-aminolevulinic acid in humans. , 1998, Journal of photochemistry and photobiology. B, Biology.

[5]  L. Baert,et al.  Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder. , 1995, Urology.

[6]  A. Neuberger,et al.  The metabolism of δ-aminolaevulic acid. 1. Normal pathways, studied with the aid of 15N , 1956 .

[7]  P Schneede,et al.  Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. , 2001, Urology.

[8]  T. Wieman,et al.  Complications of whole bladder dihematoporphyrin ether photodynamic therapy. , 1989, The Journal of urology.

[9]  R. Baumgartner,et al.  Integral photodynamic treatment of refractory superficial bladder cancer. , 1995, The Journal of urology.

[10]  U. Nseyo,et al.  Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. Bladder Photofrin Study Group. , 1998, The Journal of urology.

[11]  H Stepp,et al.  Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. , 1996, The Journal of urology.

[12]  M. Snell,et al.  Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. , 1976, The Journal of urology.

[13]  P. Okunieff,et al.  Phase I trial of photo dynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder , 1997 .

[14]  A. Straughn,et al.  Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. , 2002, The Journal of pharmacology and experimental therapeutics.

[15]  E Unsöld,et al.  Clinical experience with the integral photodynamic therapy of bladder carcinoma. , 1990, Journal of photochemistry and photobiology. B, Biology.

[16]  Manyak Mj Photodynamic therapy: principles and urologic applications. , 1991 .

[17]  R. Knuechel,et al.  Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5‐aminolevulinic acid–induced protoporphyrin IX as sensitizer , 2001, International journal of cancer.

[18]  The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer. , 2000, The Urologic clinics of North America.

[19]  J Moan,et al.  5‐Aminolevulinic acid‐based photodynamic therapy , 1997, Cancer.

[20]  B. Henderson,et al.  PHOTOSENSITIZATION OF MURINE TUMOR, VASCULATURE and SKIN BY 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRIN , 1995, Photochemistry and photobiology.

[21]  H Stepp,et al.  Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. , 1998, The Journal of urology.

[22]  S. C. Chang,et al.  Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes. , 1996, The Journal of urology.

[23]  J. H. Kinsey,et al.  Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy. , 1983, The Journal of urology.

[24]  U. Nseyo,et al.  Whole bladder photodynamic therapy: critical review of present-day technology and rationale for development of intravesical laser catheter and monitoring system. , 1990, Urology.

[25]  V. Kosma,et al.  The morphological changes in rat bladder after photodynamic therapy with 5‐aminolaevulinic acid‐induced protoporphyrin IX , 2000, BJU international.

[26]  R Baumgartner,et al.  Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. , 1994, Urology.